UK's NHS ready for CAR-T roll-out after Gilead deal

5 October 2018

A month after the UK's National Health Service (NHS) agreed a deal to make Novartis’ (NOVN: VX) Kymriah (axicabtagene ciloleucel) available to children and young people with a rare form of leukemia, a deal has been announced to bring another CAR-T therapy to English patients.

This time, the company that has reached an agreement with NHS England is US biotech Gilead Sciences (Nasdaq: GILD), and t he drug is Yescarta (axicabtagene ciloleucel); the patient group is adults whose large cell lymphoma has returned or has stopped responding to previous treatment.

Yescarta is another personalized CAR-T therapy, a new type of medicine that works by re-programming the patient’s own immune system to target their cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK